SCHEMBL6267384

SCHEMBL6267384

NC(=O)C1CCC=CCC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.41
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ATM Q13315 1/20 0.38
CYP2D6 P10635 1/20 0.38
GAA P10253 2/20 0.36
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP3A4 P08684 1/20 0.36
MEN1 O00255 1/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
ESR2 Q92731 1/20 0.36
CYP2C19 P33261 1/20 0.36
TSHR P16473 1/20 0.35
PKM P14618 1/20 0.34
MIF P14174 1/20 0.34
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21546125 0.91 MAPT (0.42) SMN1; SMN2MAPTKMT2AKDM4EATM
SCHEMBL16587928 0.87
SCHEMBL4612793 0.87
SCHEMBL15929785 0.87
SCHEMBL1385858 0.83
Hydrochloric Acid SCHEMBL27755494 0.81 SMN1; SMN2 (0.40) SMN1; SMN2MAPTKMT2AKDM4EATM
Cyclopropanecarboxylic Acid Amide SCHEMBL5661 0.78
SCHEMBL9797557 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MAPTKMT2AKDM4EATM
Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MAPTKMT2AKDM4EATM
SCHEMBL28418543 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MAPTKMT2AKDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1856297-A Pharmaceutical composition for solubility enhancement of hydrophobic drugs SANDOZ AG (CH) 2006-11-01 CN claimed
WO-2026098567-A1 MACROCYCLIC COMPOUNDS AND USE THEREOF 微境生物医药科技(上海)有限公司 2026-05-15 WO disclosed
CN-1856297-A Pharmaceutical composition for solubility enhancement of hydrophobic drugs SANDOZ AG (CH) 2006-11-01 CN disclosed
EP-1596844-A2 USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS Dynogen Pharmaceuticals Inc. (US) 2005-11-23 EP disclosed
WO-2004066987-A2 USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS DYNOGEN PHARMACEUTICALS, INC. (US) 2004-08-12 WO disclosed
US-5760246-A ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS BRISTOL-MYERS SQUIBB COMPANY 1998-06-02 US disclosed
EP-0012523-A1 Therapeutic compositions with enhanced bioavailability and process for their preparation AMERICAN HOME PRODUCTS CORPORATION (US) 1980-06-25 EP disclosed